Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer

Genomic sequencing helps identify best candidates for adjuvant chemo in colorectal cancer

Mantle cell lymphoma: A review of data and expert opinion from ASCO 2014

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early-stage HER2-positive breast cancer

First-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy provide similar survival benefit for patients with metastatic colorectal cancer

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Adjuvant exemestane more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

Comment: Advances in lung cancer presented at ASCO 2014